Clinical trials: Acquired Immune Deficiency Syndrome
HIV/AIDS
Reaching 90% HIV Suppression: The Role of POC Viral Load Monitoring in Nigeria
The UNAIDS 90-90-90 goals represents an ambitious strategy to end the acquired immunodeficiency syndrome (AIDS) epidemic by 2020 [UNAIDS, 2015].
- Trial name
- POC (NCT03533868)
- Testing
- Point-of-care viral load monitoring test
- Where
- 2 sites in Nigeria
- Volunteers
- 543 people
- Sponsor
- Harvard School of Public Health (HSPH)
Hypertension, HIV
Community Health Worker Optimization of Antihypertensive Care in HIV
To adapt and assess the implementation and preliminary effectiveness of an integrated COBRA and CHAMP multi-component community health worker-delivered hypertension intervention in improving blood pressure control among PLWH in…
- Trial name
- COACH (NCT06503991)
- Testing
- Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP), Control of Blood Pressure and Risk Attenuation (COBRA)
- Where
- Tanzania
- Volunteers
- 100 people
- Sponsor
- Duke University
Pregnancy Prevention
Continuous Use of COCs
The primary objective is to determine if continuous COC use leads to higher continuation rates over 12 months of follow up than use of the standard 28-day COC regimen.
- Trial name
- NCT00570440
- Testing
- Oral contraceptives--ethinyl estradiol, levonorgestrel
- Where
- 2 sites in Dominican Republic, Nicaragua
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection
At the end of 2004 there were more than 40 million people infected Worldwide with HIV, with an estimated 16,000 new infections every day (UNAIDS, 2004).
- Trial name
- NCT00390078
- Testing
- MVA-mBN32, IMVAMUNE
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Bavarian Nordic
Cytomegalovirus Retinitis, HIV Infections
An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving…
- Trial name
- NCT00002015
- Testing
- Ganciclovir
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roche Global Development
HIV Infections
A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC
To determine if alternating zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) (first one and then the other) or intermittent therapy (1 week of drug then 1 week off) will lessen the toxic effects of either drug alone, while…
- Trial name
- NCT00000718
- Testing
- Zidovudine, Zalcitabine
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir…
- Trial name
- NCT01565850
- Testing
- D/C/F/TAF, DRV, COBI
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COB/FTC/TAF) is a coformulated STR, is the only protease inhibitor based STR, and is noted for its high tolerability3.
- Trial name
- SymITA (NCT04240210)
- Testing
- Symtuza
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Midland Research Group, Inc.
HIV/AIDS, Hypertension
Integration of Hypertension Management in HIV Care in Uganda
Effective, cost-effective, scalable, sustainable, and equitable implementation strategies to improve care for people living with HIV and co-morbid hypertension in sub-Saharan Africa are urgently needed.
- Trial name
- PULESAUganda (NCT05609513)
- Testing
- HTN-BASIC, HTN-PLUS
- Where
- 16 sites in Uganda
- Volunteers
- 87,421 people
- Sponsor
- Infectious Diseases Research Collaboration, Uganda
Risk Behavior, HIV/AIDS
Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs
This study will evaluate the efficacy and cost-effectiveness of CHRP-BB - an integrated bio-behavioral approach that incorporates the use of PrEP - with an evidence-based behavioral approach aimed at enhancing PrEP adherence and…
- Conditions
- Risk Behavior, HIV/AIDS, Medication Adherence, Substance Abuse
- Trial name
- CHRP-BB (NCT03282890)
- Testing
- CHRP-BB
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- University of Connecticut
Infection, Human Immunodeficiency Virus
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
GSK has in-licensed a novel NNRTI-class candidate (GSK2248761, IDX12899) for the treatment of subjects with HIV-1 infection from Idenix Pharmaceuticals.
- Trial name
- NCT00945282
- Testing
- GSK2248761, Lopinavir/ritonavir, HAART
- Where
- Argentina
- Volunteers
- 8 people
- Sponsor
- ViiV Healthcare
Tobacco Use Cessation
Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study
The goal of this research study is to learn about 2 different interactive methods that are designed to help people with HIV/AIDS stop smoking.
- Trial name
- NCT02302859
- Testing
- Nicotine Patch, Questionnaires, Pamphlet
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH…
- Trial name
- NCT00000822
- Testing
- Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients
The pathophysiology from anal HPV infection to Anal Intraepithelial Neoplasia is less well understood than cervical HPV infection.
- Trial name
- GAIN (NCT03742375)
- Testing
- HPV genotyping
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hiv, Sexual Behavior
Development of a Telehealth-delivered Peer Navigation and Coping Skills Intervention to Increase PrEP Use in Young Black MSM
This proposal seeks to adapt an existing peer navigation protocol (by adding coping skills and using telehealth) to be feasible, acceptable, and capable of supporting both PrEP uptake and P-E adherence for YBMSM ages 15-24.
- Trial name
- NCT05769270
- Testing
- Peer Navigation and Coping Skills, Treatment as Usual
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Infection, Human Immunodeficiency Virus
Single and Repeated Dose Escalation Study of GSK2838232
GSK2838232 is a Human Immunodeficiency Virus (HIV) maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy (ART).
- Trial name
- NCT02795754
- Testing
- GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV/AIDS
DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV
This study is a prospective single arm open label intervention study over 16 weeks using the DHFS and a telemedicine platform with persons living with HIV who are not virologically suppressed, admitted to UCSD Hillcrest Medical…
- Trial name
- NCT04418037
- Testing
- Digital Health Feedback System(DHFS)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
HIV/AIDS
HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions
A clinical study for patients with HIV that investigates the best way to reduce HIV transmission risk, and to improve the overall health of people living with HIV/AIDS.
- Trial name
- WELL (NCT03238586)
- Testing
- WELL Program
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Human Immunodeficiency Virus, Herpes Simplex Type II
MAMAS: Mentoring Adolescent Mothers at School
This study aims to evaluate the efficacy of an intervention designed to reduce STI/HIV incidence by increasing the number of adolescent mothers who re-enroll and remain in school.
- Conditions
- Human Immunodeficiency Virus, Herpes Simplex Type II, Chlamydia, Gonorrhea
- Trial name
- MAMAS (NCT03090802)
- Testing
- Mentoring Adolescent Mothers at School (MAMAS)
- Where
- South Africa
- Volunteers
- 152 people
- Sponsor
- Drexel University
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)